Loading...

Erasca, Inc.

ERAS•NASDAQ
Healthcare
Biotechnology
$21.49
$-0.98(-4.36%)
U.S. Market opens in 49h 27m

Erasca, Inc. (ERAS) Stock Overview

Explore Erasca, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap6.7B
P/E Ratio-48.70
EPS (TTM)$-0.44
ROE-0.34%
Fundamental Analysis

AI Price Forecasts

1 Month$17.41
3 Months$27.87
1 Year Target$9.88

ERAS Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Erasca, Inc. (ERAS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 67.06, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $9.88.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -48.70 and a market capitalization of 6.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-4.32%
5-Day Change
15.53%
1-Month Change
46.56%
3-Month Change
115.86%
6-Month Change
803.36%
Year-to-Date (YTD) Change
477.96%
1-Year Change
1435.71%
3-Year Change
696.30%
5-Year Change
23.35%
All-Time (Max) Change
23.35%

Contact Information

https://www.erasca.com
858 465 6511
10835 Road to the Cure, San Diego, CA, 92121

Company Facts

103 Employees
IPO DateJul 16, 2021
CountryUS
Actively Trading

Frequently Asked Questions